FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable products. In addition, it engages in research and development, storage, and cryopreservation of sperm and oocytes for use in reproductive medicine; and the manufacturing and distribution of medical devices. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is headquartered in Leipzig, Germany.
Frequently asked questions
What sector does VITA 34 AG (VTIAF) operate in?
VITA 34 AG belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is VITA 34 AG (VTIAF) current stock price?
As of the latest data, VITA 34 AG stock price is $3.10, with a previous close of $3.10.
What is VITA 34 AG (VTIAF) current market capitalization?
VITA 34 AG market cap is approximately 54.04 million.
What is VITA 34 AG (VTIAF) Earnings Per Share (EPS)?
The trailing EPS is -$0.43.
What is VITA 34 AG (VTIAF) EBITDA?
VITA 34 AG EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.41 million.
Does VITA 34 AG (VTIAF) pay dividends?
No. VITA 34 AG does not pay a dividend.
What is VITA 34 AG (VTIAF) beta (volatility) score?
VITA 34 AG has a beta of 0.642, indicating lower volatility than the overall market.
